David Sebag-Montefiore, Director at Leeds Cancer Research UK Radiotherapy Research Centre of Excellence, shared a post on LinkedIn:
“It was a great privilege to present the mature results of the Cancer Research UK (CRUK) funded ARISTOTLE rectal cancer trial that evaluated the addition of concurrent irinotecan to capecitabine chemoradiation in the top clinical trials session at ESTRO25 in Vienna.
589 patients with MRI-defined high risk rectal cancer were randomised 1:1 to receive IrCRT or CRT
Higher acute toxicity and reduced capecitabine compliance in the IrCRT arm
No evidence of an improvement in disease free survival
Very low (5%) rates of loco-regional failure indicating high quality multidisciplinary care
A huge than you to the patients who took part, Cancer Research UK (CRUK) who funded the trial and the 75 UK sites who participated
Further translational work is planned, building on three published predictive biomarker studies including ARISTOTLE CRT patient samples, to determine predictive biomarkers of response to IrCRT”
More posts about ESTRO 2025 on OncoDaily.
